Phaseline

Targets › LGR5

LGR5 (Leucine-rich repeat-containing G protein-coupled receptor 5): drug programs, companies and trials

1 program from 1 company in 5 trials: 4 Phase 3, 1 Phase 1; Oncology; next expected readout Jan 2028.

Receptor for R-spondins that potentiates the canonical Wnt signaling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle. Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes. (UniProt, O75473)

Open in Phaseline: the race on LGR5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
GenmabPetosemtamab (MCLA-158)
bispecific antibody targeting EGFR and LGR5
EGFR, CEACAM5, LGR5Phase 3Head and Neck Squamous Cell Carcinoma; Colorectal Cancer; Left-sided Colorectal Cancer; Advanced/Metastatic Solid TumorsJan 2028

Conditions

Head and Neck Squamous Cell Carcinoma (2) Colorectal Cancer (1) Left-sided Colorectal Cancer (1) Advanced/Metastatic Solid Tumors (1)

Modalities

antibody (1)

Companies

Genmab (1)

Related targets

EGFR (1) CEACAM5 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.